icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
the actual benefit of HEMANGIOL 3.75 mg/ml oral solution is substantial in the indication in the Marketing Authorisation.
Clinical Added Value
moderate
HEMANGIOL 3.75 mg/ml oral solution provides a moderate improvement in actual benefit (IAB III) in the treatment of proliferating infantile haemangioma requiring systemic therapy.
eNq1mF1v2jAUhu/5FVHuSYBCP6ZAtbF2Q2o1Ros27QaZ5FDMjJ0e20D36+cQutHJUVeDLxM77znxef34yMnlZsmCFaCkgnfDZtQIA+CpyCh/6Ibj++v6eXjZqyULsiJ708y8qNUKg5QRKbthMRpNgXAZfb+9+Qjme8CwVwsSMV1Aql7M04qy6DOR81uSF3OCZCVoFixBzUXWDXOttm+DRCo0WfTWAn/KnKSQxLs3+6OLSXv/fRIXYv+hqiXgDeEPVlHgTpqpRgSu+kTBg8CninxPnLSpHIEUGlMYEjUfoljRDDJriBlhEpyCzNbZHeCKgSqCWMXjRbqUTuJkQTYjeBzYk35vRvtqo+qNevOs1Wq0T09bFyfNhlMo3FsqexXMT8TppHnWOblod2Lg8RyWxg1UMMfqDAUqwjzVhcr+S2t5ioPw+Gr9MypzRp6ihcxdl4ogMcOABgD+fqT4g3s0SGJmzf7R55qx+I1Zj3fA8JRxwaO+0FxVcON65LoQfcEVbKor6oY6tdl5kYI8nuwvwe2YH+opo6kr1Ax2NEg1Hg2qmXZcHHwgEsbojwffKM/EWh6fM/t19ZR9vkWlVTTHrDlpXZyfNjsd5230w5io4pS50ihyiA2BqDwELAM+E4cixfjSLvXsyiMactvtiJQwqOh36o58MU58bs+8ed3fPioHrKKfru5dDfJVAz7dbR+t0jTr/imtG3x9EN3YsTLxt5u73ONeOmGNdnbMlcrluzher9fRnMi6JGaVohl6oPvekeqvE/dybpd9TElIT6lPy6PvbTVy3WuvneyHdqu773ddsTWGQg0H1KLEsjd4Dq6Oz+O/raq3tIcv+OEvzLatJIoK7qvZ0VOr4mEngKkrv0YDiC+zGa24Gan0ZRKXtzK9WhIXNzK92m8bbOfY
tCTaQpvRYFrRyxQd